.webp&w=384&q=75){kind=logo}
Loading, please wait...
Loading, please wait...
The role of ketogenic diet therapy in very young infants with drug-resistant epilepsy has been less certain than in older children. The KIWE trial was a multicentre randomized study comparing a classic ketogenic diet with another antiseizure medication in infants aged one to 24 months. The study found no clear difference between groups in median seizure frequency during the primary eight-week assessment period. The trial was stopped early because of slow recruitment and funding limitations, reducing its ability to detect modest treatment differences. The result is important because it tempers assumptions that ketogenic therapy should automatically replace another medication as the next step in every infant with drug-resistant epilepsy. At the same time, the study does not show that ketogenic therapy is ineffective in infancy; rather, the evidence was underpowered and the population was clinically heterogeneous. For HCPs, treatment decisions should consider epilepsy syndrome, underlying cause, feeding capacity, nutritional status, medication history and family preferences. The study demonstrates why age-specific evidence matters when applying dietary therapies to children with severe epilepsy.
Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.
Open your smartphone camera to scan and install.
The role of ketogenic diet therapy in very young infants with drug-resistant epilepsy has been less certain than in older children. The KIWE trial was a multicentre randomized study comparing a classic ketogenic diet with another antiseizure medication in infants aged one to 24 months. The study found no clear difference between groups in median seizure frequency during the primary eight-week assessment period. The trial was stopped early because of slow recruitment and funding limitations, reducing its ability to detect modest treatment differences. The result is important because it tempers assumptions that ketogenic therapy should automatically replace another medication as the next step in every infant with drug-resistant epilepsy. At the same time, the study does not show that ketogenic therapy is ineffective in infancy; rather, the evidence was underpowered and the population was clinically heterogeneous. For HCPs, treatment decisions should consider epilepsy syndrome, underlying cause, feeding capacity, nutritional status, medication history and family preferences. The study demonstrates why age-specific evidence matters when applying dietary therapies to children with severe epilepsy.
Today
The phase 3 ACACIA-HCM trial reveals that aficamten improves cardiac structure, diastolic relaxation, functional capacity, and symptom burden in symptomatic nonobstructive hypertrophic cardiomyopathy, marking a major milestone in targeted myosin inhibition.
6 days back
A clinical study shows that automated breast ultrasound paired with artificial intelligence accurately classifies BIRADS 3-4 lesions, reaching 95% sensitivity and 79% specificity. This diagnostic advance promises to reduce unnecessary core needle biopsies and refine clinical workflows in breast imaging.
3 weeks back
Researchers have engineered freestanding hierarchical-porous BCZT thin films that resist cracking and enhance ultrasonic energy harvesting in soft tissue. Achieving high piezoelectric output and acoustic matching, this lead-free material offers transformative potential for implantable bioelectronics.
6 days back
A novel pathology-adaptive surface engineering strategy uses functionalized plasma polymer coatings to selectively modulate AGE adsorption, reducing oxidative stress and restoring bone formation in diabetic and aging microenvironments.
3 weeks back
A breakthrough study identifies the Klotho/PKCα/CUX1/SPARC/TGFβ-RII axis as a critical driver of podocyte mitochondrial injury and ferroptosis in diabetic kidney disease, unveiling promising molecular targets to halt renal disease progression.
6 days back
